Efficacy of azithromycin hydrate ophthalmic solution for treatment of internal hordeolum and meibomitis with or without phlyctenular keratitis.
Azithromycin
Cutibacterium acnes
Meibomian gland dysfunction
Meibomitis
hordeolum
Journal
Japanese journal of ophthalmology
ISSN: 1613-2246
Titre abrégé: Jpn J Ophthalmol
Pays: Japan
ID NLM: 0044652
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
received:
02
12
2022
accepted:
14
06
2023
medline:
1
9
2023
pubmed:
16
7
2023
entrez:
15
7
2023
Statut:
ppublish
Résumé
To evaluate the efficacy of azithromycin hydrate ophthalmic solution for the treatment of internal hordeolum and meibomitis with or without phlyctenular keratitis. Retrospective study. Patients diagnosed with internal hordeolum or meibomitis were prescribed azithromycin hydrate ophthalmic solution twice daily for 2 days and then once daily for 12 days. Depending on the presence of meibomitis-related keratoconjunctivitis (MRKC), we further divided the patients with meibomitis into three subgroups: meibomitis alone (non-MRKC group), meibomitis with non-phlyctenular MRKC (non-phlyctenular group), and meibomitis with phlyctenular MRKC (phlyctenular group). Inflammatory findings (eyelid redness and conjunctival hyperemia) were scored before and after treatment. Some patients also underwent culture testing fluids discharged by the meibomian gland orifices. Three patients (3 eyes) had internal hordeolum and 16 patients (16 eyes) had meibomitis. After treatment, the inflammatory findings disappeared in all eyes with internal hordeolum. Among the patients with meibomitis, three eyes were in the non-MRKC, six in the non-phlyctenular, and seven in the phlyctenular group. The inflammatory findings were significantly improved only in the phlyctenular group. Among seven eyes with positive culture results, Cutibacterium acnes was detected in five, and treatment improved the inflammatory findings in all of these eyes. Azithromycin hydrate ophthalmic solution is effective for the treatment of inflammatory meibomian gland diseases, including internal hordeolum and meibomitis. In particular, the agent is highly efficient in patients with phlyctenular MRKC.
Identifiants
pubmed: 37453929
doi: 10.1007/s10384-023-01010-w
pii: 10.1007/s10384-023-01010-w
doi:
Substances chimiques
Azithromycin
83905-01-5
Ophthalmic Solutions
0
Anti-Bacterial Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
565-569Informations de copyright
© 2023. Japanese Ophthalmological Society.
Références
McCulley JP, Dougherty JM, Deneau DG. Classification of chronic blepharitis. Ophthalmology. 1982;89:1173–80.
doi: 10.1016/S0161-6420(82)34669-2
pubmed: 6218459
Nichols KK, Foulks GN, Bron AJ, Glasgow BJ, Dogru M, Tsubota K, et al. The international workshop on meibomian gland dysfunction: Executive summary. Investig Ophthalmol Vis Sci. 2011;52:1922–9.
doi: 10.1167/iovs.10-6997a
McCulley JP, Sciallis GF. Meibomian keratoconjunctivitis. Am J Ophthalmol. 1977;84:788–93.
doi: 10.1016/0002-9394(77)90497-4
pubmed: 145804
Suzuki T. Inflamed obstructive meibomian gland dysfunction causes ocular surface inflammation. Investig Opthalmology Vis Sci. 2018;59:DES94.
doi: 10.1167/iovs.17-23345
Suzuki T, Teramukai S, Kinoshita S. Meibomian glands and ocular surface inflammation. Ocul Surf. 2015;13:133–49.
doi: 10.1016/j.jtos.2014.12.002
pubmed: 25881997
Akpek EK, Vittitow J, Verhoeven RS, Brubaker K, Amar T, Powell KD, et al. Ocular surface distribution and pharmacokinetics of a novel ophthalmic 1% azithromycin formulation. J Ocul Pharmacol Ther. 2009;25:433–9.
doi: 10.1089/jop.2009.0026
pubmed: 19857105
Luchs J. Azithromycin in durasite® for the treatment of blepharitis. Clin Ophthalmol. 2010;4:681–8.
doi: 10.2147/OPTH.S6370
pubmed: 20689782
pmcid: 2915852
Foulks GN, Borchman D, Yappert M, Kim S-H, McKay JW. Topical azithromycin therapy for Meibomian Gland Dysfunction: clinical response and lipid alterations. Cornea. 2010;29:781–8.
doi: 10.1097/ICO.0b013e3181cda38f
pubmed: 20489573
pmcid: 2893269
Arita R, Fukuoka S. Efficacy of azithromycin eyedrops for individuals with Meibomian Gland Dysfunction-Associated posterior blepharitis. Eye Contact Lens. 2021;47:54–9.
doi: 10.1097/ICL.0000000000000729
pubmed: 32649390
Nejima R, Eguchi H, Todokoro D, Inoue T, Kaji Y, Suzuki T, et al. Analysis of treatment protocols using azithromycin eye drops for bacterial blepharitis: second report—bacteriological investigation. Jpn J Ophthalmol. 2022;66:579–89.
doi: 10.1007/s10384-022-00947-8
pubmed: 36181644
Haque RM, Torkildsen GL, Brubaker K, Zink RC, Kowalski RP, Mah FS, et al. Multicenter open-label study evaluating the efficacy of azithromycin ophthalmic solution 1% on the signs and symptoms of subjects with blepharitis. Cornea. 2010;29:871–7.
doi: 10.1097/ICO.0b013e3181ca38a0
pubmed: 20508503
Ciloglu E, Özcan AA, Incekalan T, Unal F. The role of topical azithromycin in the treatment of Meibomian Gland Dysfunction. Cornea. 2020;39:321–4.
doi: 10.1097/ICO.0000000000002233
pubmed: 31842036
Gordon AA, Danek DJ, Phelps PO. Common inflammatory and infectious conditions of the eyelid. DisMon. 2020;66:101042.
Japanese Association for Ocular Infection: Guidelines for the Clinical Trials of Topical Ophthalmic Antibacterial Agent. Ministry of Health, Labour and Welfare. (in Japanese). Accessed 18 Apr 2023.
Kagkelaris KA, Makri OE, Georgakopoulos CD, Panayiotakopoulos GD. An eye for azithromycin: review of the literature. Ther Adv Ophthalmol. 2018;10:251584141878362.
doi: 10.1177/2515841418783622
Azimycin ophthalmic solution 1%. Package insert. Senju Pharmaceutical Co., Ltd; 2020. (in Japanese).
Hirunwiwatkul P, Wachirasereechai K, Khantipong M, Chongthaleong A. Identifications of hordeolum pathogens and its susceptibility to antimicrobial agents in topical and oral medications. Asian Biomed. 2012;6:297–302.
Suzuki T, Sutani T, Nakai H, Shirahige K, Kinoshita S. The microbiome of the meibum and ocular surface in healthy subjects. Investig Ophthalmol Vis Sci. 2020;61:1–7.
Suzuki T, Sano Y, Sasaki O, Kinoshita S. Ocular surface inflammation induced by Propionibacterium acnes. Cornea. 2002;21:812–7.
doi: 10.1097/00003226-200211000-00017
pubmed: 12410043
Suzuki T. Meibomitis-Related keratoconjunctivitis: implications and clinical significance of meibomian gland inflammation. Cornea. 2012;31:41–4.
doi: 10.1097/ICO.0b013e31826a04dd